Your browser doesn't support javascript.
The first case of COVID-19 treated with the complement C3 inhibitor AMY-101.
Mastaglio, Sara; Ruggeri, Annalisa; Risitano, Antonio M; Angelillo, Piera; Yancopoulou, Despina; Mastellos, Dimitrios C; Huber-Lang, Markus; Piemontese, Simona; Assanelli, Andrea; Garlanda, Cecilia; Lambris, John D; Ciceri, Fabio.
  • Mastaglio S; Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Ruggeri A; Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Risitano AM; Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy.
  • Angelillo P; Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Yancopoulou D; Amyndas Pharmaceuticals, Glyfada, Greece.
  • Mastellos DC; National Center for Scientific Research 'Demokritos', Aghia Paraskevi, Athens, Greece.
  • Huber-Lang M; Institute of Experimental Trauma-Immunology, University Hospital of Ulm, Ulm, Germany.
  • Piemontese S; Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Assanelli A; Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Garlanda C; IRCCS Humanitas Clinical and Research Center, Milan, Italy; Humanitas University, Milan, Italy.
  • Lambris JD; Department of Pathology & Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: lambris@pennmedicine.upenn.edu.
  • Ciceri F; Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; University Vita Salute San Raffaele, Milan, Italy. Electronic address: ciceri.fabio@hsr.it.
Clin Immunol ; 215: 108450, 2020 06.
Article in English | MEDLINE | ID: covidwho-172295
ABSTRACT
Acute respiratory distress syndrome (ARDS) is a devastating clinical manifestation of COVID-19 pneumonia and is mainly based on an immune-driven pathology. Mounting evidence suggests that COVID-19 is fueled by a maladaptive host inflammatory response that involves excessive activation of innate immune pathways. While a "cytokine storm" involving IL-6 and other cytokines has been documented, complement C3 activation has been implicated as an initial effector mechanism that exacerbates lung injury in preclinical models of SARS-CoV infection. C3-targeted intervention may provide broader therapeutic control of complement-mediated inflammatory damage in COVID-19 patients. Herein, we report the clinical course of a patient with severe ARDS due to COVID-19 pneumonia who was safely and successfully treated with the compstatin-based complement C3 inhibitor AMY-101.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Peptides, Cyclic / Pneumonia, Viral / Complement C3 / Coronavirus Infections / Complement Activation / Complement Inactivating Agents / Betacoronavirus Type of study: Case report / Observational study / Prognostic study Language: English Journal: Clin Immunol Journal subject: Allergy and Immunology Year: 2020 Document Type: Article Affiliation country: J.clim.2020.108450

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Peptides, Cyclic / Pneumonia, Viral / Complement C3 / Coronavirus Infections / Complement Activation / Complement Inactivating Agents / Betacoronavirus Type of study: Case report / Observational study / Prognostic study Language: English Journal: Clin Immunol Journal subject: Allergy and Immunology Year: 2020 Document Type: Article Affiliation country: J.clim.2020.108450